Mycobacterium xenopi in HIV-infected patients: an emerging pathogen.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Mycobacterium xenopi in HIV-infected patients: an emerging pathogen.

AIDS. 1998 Sep 10;12(13):1661-6. Unique Identifier : AIDSLINE MED/98435815
Juffermans NP; Verbon A; Danner SA; Kuijper EJ; Speelman P; Department of Internal Medicine, University of Amsterdam, The; Netherlands.

Abstract: BACKGROUND: Mycobacterium xenopi is associated with pulmonary disease in patients with loss of local or general host defence. OBJECTIVES: To determine the occurrence of M. xenopi in our hospital during 1987-1992 and 1993-1996, as well as the association of M. xenopi with HIV infection in 1993-1996; to evaluate the clinical significance of M. xenopi in HIV-seropositive patients. DESIGN: Retrospective review of charts and classification of patients based on earlier definitions derived from the American Thoracic Society. SETTING: Tertiary hospital. PATIENTS: Patients with a positive isolate of M. xenopi from January 1987 until December 1996. MAIN OUTCOME MEASURES: During 1993 1996, a significant increase in the number of patients with M. xenopi was found compared with 1987-1992. Of 25 patients, 22 were HIV-seropositive. RESULTS: The HIV-seropositive patients were classified as having definite (n = 5), probable (n = 9) and unlikely disease (n = 8) due to M. xenopi. Symptoms, median CD4 cell count, treatment and outcome did not differ between these groups. CONCLUSIONS: M. xenopi is an emerging pathogen, especially in HIV-infected patients. The criteria of the American Thoracic Society for disease due to non-tuberculous mycobacteria do not seem applicable to M. xenopi in HIV-infected patients. We suggest that two positive cultures of M. xenopi and no other likely cause of symptoms present should be considered the criteria for diagnosis of M. xenopi disease in HIV-infected patients.

Keywords: JOURNAL ARTICLE Adult Female Human HIV Infections/COMPLICATIONS/*MICROBIOLOGY Male Middle Age *Mycobacterium xenopi/ISOLATION & PURIF Mycobacterium Infections, Atypical/COMPLICATIONS/*EPIDEMIOLOGY Netherlands/EPIDEMIOLOGY Pneumonia, Bacterial/COMPLICATIONS/*EPIDEMIOLOGY Retrospective Studies Support, Non-U.S. Gov't
990228
A9920963

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .